Soheila Karimi-Neural Regeneration & Stem Cell Dr. April Lussier (she/her) 🇨🇦 @Mojtaba42459247 University of Manitoba CIHR CAN ACN Anyway this can help neuron recovery and replacement in #ALS patients? #endals

Hey Elon Musk maybe we could throw a few billion at curing terminal illnesses like ALS. If you want to save the planet, let's start with saving the people on it like my brother Stew #endALS #iamALS #flexonALS #dyingwaiting

U.S. FDA Please use regulatory flexibility and approve the other drugs stalled- Amx0035 and nurown. We need more options for this 100% fatal disease.

PROACTIVE, an essential word for the approval of treatments for ALS, Suivez-nous @GouvCanSante Jean-Yves Duclos Justin Trudeau Luc Thériault Marie-Hélène Gaudreau, députée show us that we can count on you. ALS is fatal and fast.Société de la SLA du Québec | ALS Society of QC ALS Canada

Dear U.S. FDA when delaying the Amylyx decision did you think #everypointmatters on the ALSFRS-R? Can you imagine drooling w/out control becoming a soggy mess?Excess of saliva w/some drooling(1pt) to marked drooling requiring constant attention(0pt).1pt is a BIG deal!

Dear U.S. FDA when you delayed safe & effective AMX0035 Amylyx did you think of lost points in hand dexterity (handwriting)?4,3,2,1,0(pt) ends in paralization, so #everypointmatters.Loss of grip strength means modifications are needed for "exercise."

Dear U.S. FDA did you think of those families missing Dads #FathersDay2022 & how #everypointmatters on the ALSFRS-R score?3 amazing Dads here but no longer.Celebrating these 2 is different as bitterness tinges joy.Remind me why you delayed Amylyx?A pt means what to you?

Dear U.S. FDA unless you are up close to ALS you struggle to understand how swift this disease moves & that #everypointmatters! These two loved running together but their outdoor adventures had to shift drastically.Time is of the essence; the delay of Amylyx is cruel.

Mark, an ALS warrior who advocated for all of us is gone Tracy Beth Høeg, MD, PhD Dr. Robert M. Califf U.S. FDA . PLEASE make the dying stop. Please approve AMX0035 immediately then go forward with urgency for all other ALS drug approvals. #everypointmatters

Today, U.S. FDA announced expedited review for lecanemab, a new Alzheimer's drug from Biogen. This follows yesterday's announcement of a second adcom for AMX0035. I am cheering for the Alzheimer's community but pissed off for the ALS community. Prove me wrong, U.S. FDA, please.

Today again proves even when new #ALS drugs "fail" due to the most difficult trials & circumstances for the most catastrophic disease ever, SOME benefit. And for ALS, "some" is good enough. It is time to file, BrainStorm. 30k+ pALS are ready to🥊🥊 biospace.com/article/releas…

Adam Feuerstein ✡️ Your reporting is inaccurate. You cited an #FDA letter that is now over 1.5 years old, and based on incorrect data and/or false information that implied a "death risk" with #NurOwn. There is NO such risk. You also failed to add key relevant context that AMX0035 had a 4-6 ADCOM.

Adam Feuerstein ✡️ 2/ Suggest you read this very accurate piece from BioSpace for clarification, and to read the complete story for future basis. Disappointing oversights. biospace.com/article/brains…

Igor Moura 🇧🇷 🎪🎠🤡🍿 NervGen Pharma Corp. Health Europa Agreed. I wonder if FDA is involved and working fast enough for the Nuro degenerative diseases.

.Hande Ozdinler, I was wondering if you can give a status update on the NU-9 preclinical studies. When do you think it will be ready for a phase 1 clinical trial? I'm excited to see if the impact on upper motor neurons is as profound in humans. I hope it's moving forward quickly.

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in #AmyotrophicLateralSclerosis (#ALS). Read the full news release here: bit.ly/3Q3OY9X #ALSAwareness #Biotech #Neurology #Research #Science #Tcells

💥| Gizli gizli fotoğraf çeken taksici böyle yakalandı